Compare GP & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GP | PFSA |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 3.7M |
| IPO Year | 2013 | N/A |
| Metric | GP | PFSA |
|---|---|---|
| Price | $1.03 | $0.86 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 152.0K | ★ 258.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $0.05 |
| 52 Week High | $4.00 | $4.22 |
| Indicator | GP | PFSA |
|---|---|---|
| Relative Strength Index (RSI) | 46.75 | 43.75 |
| Support Level | $0.87 | $0.85 |
| Resistance Level | $1.07 | $2.22 |
| Average True Range (ATR) | 0.09 | 0.18 |
| MACD | -0.02 | -0.12 |
| Stochastic Oscillator | 14.89 | 0.55 |
GreenPower Motor Co Inc is the manufacturer and distributor of all-electric charter, school, and city buses. The company offers electric-powered transit buses deploying electric drive and battery technologies with a lightweight chassis and low-floor body. Its product line includes all-electric transit buses, all-electric school buses, and shuttle buses. The company's buses depend on clean sheet design and utilize a custom battery management system and a proprietary flex power system for the drive motors. Geographically, the company generates a majority of its revenue from the United States of America and the rest from Canada.
Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.